Free Newsletter
'Obesity gene' could be key to new therapy
The quest for a new obesity drug took a big step forward with new research from Germany demonstrating how a drug that knocks out the FTO 'obesity gene' could help slim down the world's growing population of obese patients.
Scientists already knew that the FTO gene could add 6.6 pounds to the average frame. Knocking out that gene in mice allowed them to burn calories at a faster pace. And the researchers found that the mice that were engineered without the FTO gene had higher levels of adrenaline.
"These animals are eating as much as the control animals but burning calories through a non-exercise mediated pathway," said one expert, Dr. Stuart Weiss, a clinical assistant professor of medicine at New York University School of Medicine. But Weiss also concedes that the researchers don't know exactly why the process was taking place,
By the age of six weeks, according to the study, the knock-out mice weighed 30 to 40 percent less than the 'normal' mice in the control group.
- read the report from Forbes
Related Articles:
Obesity researchers finger cold virus as culprit
Enzyme could be key to controlling obesity
Scripps Research team finds new obesity target
Genetic tinkering creates obesity-resistant mice
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: